GSK621 (GSK-621) is a potent, specific AMPK agonist (activator), induces cytotoxicity in AML (IC50=13-30 uM) but not in normal hematopoietic cells.
GSK621 is more potent than A-769662 at inducing AMPK activation, as measured by the level of ACC phosphorylation, markedly increases phosphorylation at AMPKα T172 in AML cell lines (MOLM-14, HL-60, and OCI-AML3) and primary AML samples.
Cytotoxicity in AML cells from GSK621 involves the eIF2α/ATF4 signaling pathway that specifically results from mTORC1 activation.
